Quantcast
Home > Quotes > CNCE
CNCE

Concert Pharmaceuticals, Inc. Common Stock (CNCE) Quote & Summary Data

$16.2315
*  
0.1085
0.66%
Get CNCE Alerts
*Delayed - data as of Aug. 16, 2018 14:39 ET  -  Find a broker to begin trading CNCE now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    CNCE Real Time
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
$ 16.21 / $ 16.25
Today's High / Low
$ 16.54 / $ 15.94
Share Volume
57,012
50 Day Avg. Daily Volume
160,551
Previous Close
$ 16.34
52 Week High / Low
$ 30.7074 / $ 13.57
Market Cap
379,749,187
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %

Intraday Chart

Shares Traded

Share Volume:
57,012
50 Day Avg. Daily Volume:
160,551

P/E Ratio

P/E Ratio:
3.67
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ 4.42

Trading Range

The current last sale of $16.2315 is 19.61% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 16.54 $ 30.7074
 Low: $ 15.94 $ 13.57

Company Description (as filed with the SEC)

We are a clinical stage biopharmaceutical company applying our extensive knowledge of deuterium chemistry to discover and develop novel small molecule drugs. Selective incorporation of deuterium into known molecules has the potential, on a case-by-case basis, to provide better pharmacokinetic or metabolic properties, thereby enhancing their clinical safety, tolerability or efficacy. Our approach typically starts with previously studied compounds, including approved drugs, which we believe may be improved with deuterium substitution. Our technology provides the opportunity to develop products that may compete with the non-deuterated drug in existing markets or to leverage its known activity to expand into new indications. Our deuterated chemical entity platform, or DCE Platform®, has broad potential across numerous therapeutic areas. We have a pipeline of clinical candidates as well as research efforts to identify new product candidates.  ... More ...  


Risk Grade

Where does CNCE fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 16.38
Open Date:
Aug. 16, 2018
Close Price:
N/A
Close Date:
N/A

Consensus Recommendation

Analyst Info